GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Investments And Advances
Switch to:

Biogen (MEX:BIIB) Investments And Advances

: MXN42,521 Mil (As of Mar. 2023)
View and export this data going back to 2013. Start your Free Trial

Biogen's Investments And Advances for the quarter that ended in Mar. 2023 was MXN42,521 Mil.

Biogen's quarterly Investments And Advances declined from Sep. 2022 (MXN49,742 Mil) to Dec. 2022 (MXN43,572 Mil) and declined from Dec. 2022 (MXN43,572 Mil) to Mar. 2023 (MXN42,521 Mil).

Biogen's annual Investments And Advances declined from Dec. 2020 (MXN73,026 Mil) to Dec. 2021 (MXN58,085 Mil) and declined from Dec. 2021 (MXN58,085 Mil) to Dec. 2022 (MXN43,572 Mil).


Biogen Investments And Advances Historical Data

The historical data trend for Biogen's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Investments And Advances
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60,210.73 50,184.57 73,025.52 58,085.39 43,571.61

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Investments And Advances Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55,135.55 52,381.24 49,742.38 43,571.61 42,520.98

Biogen Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines